Piper Sandler raised the firm’s price target on Indivior (INDV) to $16 from $15 and keeps an Overweight rating on the shares after Q3 earnings. Though the optics of multiple downward revisions to 2024 guidance are undoubtedly “messy,” Sublocade is growing, particularly in the context of significant underpenetration of long-acting injectable buprenorphine modalities, Piper told investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INDV:
- Indivior lowers FY24 revenue view to $1.13B-$1.17B from $1.15B-$1.22B
- Indivior, Humana and Centene report expected settlement of antitrust litigation
- Indivior reports Q3 adjusted EPS 54c, consensus 31c
- Indivior PLC Reports Strong Q3 2024 Performance
- INDV Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
